Indeed, as we previously reported, an efficient uptake of gemcitabine by cancer cells requires proper hENT-1 localization on the cell membrane, and aberrant localization of this transporter in cancer cells may result in a decreased/lack of response in patients receiving this drug [4]. Here, SLC29A1 is linked to cancer.